Result of AGM

RNS Number : 2111N

Dechra Pharmaceuticals PLC

21 October 2016

 

Date: 21 October 2016

Dechra^® Pharmaceuticals PLC

Results of Annual General Meeting (AGM)

AGM Meeting Date: 1 pm on 21 October 2016

Issued Share Capital at meeting date: 92,788,719

Number of shareholders in attendance:  14

All resolutions were passed on a show of hands.

Details of the proxy voting instructions lodged prior to the AGM are set out below:

Resolution (No. as noted on proxy form)	Total For (1)		Total Against		Withheld (2)
	No. of votes	% of vote	No. of votes	% of vote	No. of votes
Resolution 1: To receive the report and accounts	66,104,449	99.95	32,000	0.05	3,048,779
Resolution 2: To receive and approve the Directors' Remuneration Report	66,616,092	98.76	834,805	1.24	1,734,331
Resolution 3: To declare a final dividend	69,185,228	100.0	0	0	0
Resolution 4: To elect William Anthony Rice	68,046,631	98.36	1,136,347	1.64	2,250
Resolution 5: To re-elect Ian Page	67,984,340	98.27	1,198,638	1.73	2,250
Resolution 6: To re-elect Anthony Griffin	67,984,340	98.27	1,198,638	1.73	2,250
Resolution 7: To re-elect Ishbel Macpherson	69,112,391	99.90	70,587	0.10	2,250
Resolution 8: To re-elect Julian Heslop	69,149,942	99.95	33,036	0.05	2,250
Resolution 9: To re-appoint PricewaterhouseCoopers as Auditor	69,176,531	99.99	8,247	0.01	450
Resolution 10: To authorise the Directors to determine the remuneration of the Auditor	69,182,875	100	1,903	0.00	450
Resolution 11: To grant authority to allot shares to a specific limit	64,870,859	93.77	4,310,669	6.23	3,700
Resolution 12: To disapply pre-emptive rights	68,156,395	98.52	1,025,133	1.48	3,700
Resolution 13: To disapply additional pre-emptive rights	62,744,366	90.70	6,437,162	9.30	3,700
Resolution 14: To grant authority to the Company to purchase its own shares	68,620,288	99.18	564,940	0.82	0
Resolution 15: To call general meetings (other than an AGM) on not less than 14 clear days notice	66,498,105	96.12	2,684,873	3.88	2,250

Notes

1.   Includes discretionary votes.

2.   A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "For" and "Against" a resolution.

3.   Resolutions 1 to 11 were ordinary resolutions, requiring more than 50% of shareholder votes to be "for" the resolutions.

4.   Resolutions 12 to 15 were special resolutions, requiring more than 75% of shareholder votes to be "for" the resolutions.

5.   Votes tendered in respect of 69,185,228 shares representing 74.57% of the issued share capital.

In accordance with Listing Rule 9.6.2R, a copy of the resolutions passed as special business at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm.

For further information

Suzana Cross, General Counsel and Company Secretary                               

Telephone number: 01606 814730

About Dechra

Dechra is an international specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information, please visit: www.dechra.com.

Trademarks

Trademarks appear throughout this document in italics.  Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

Forward Looking Statement

This document may contain certain forward-looking statements.  The forward-looking statements reflect the knowledge and information available to the Company during the preparation and up to the publication of this document.  By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involve a degree of uncertainty.  Therefore, nothing in this document should be construed as a profit forecast by the Company.

Market Abuse Regulation (MAR)

The information contained within this announcement may contain inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.  Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

END

 

 

RAGEADEFASEKFFF